Drug intelligence / Profile preview

SGB-OB03

Development stage: Preclinical
Lead developer: Sanegene Bio
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

SGB-OB03 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Sanegene Bio (Suzhou Shengyin Biopharmaceutical) for the treatment of obesity. The drug is engineered using Sanegene's proprietary LEAD (Liver-targeting Efficient siRNA Delivery) platform, which employs GalNAc-conjugation to facilitate targeted delivery to hepatocytes. By leveraging the RNA interference (RNAi) mechanism, SGB-OB03 aims to achieve potent and long-lasting silencing of a specific gene involved in metabolic regulation. As of 2024, the program is in the Lead Identification phase, with the specific molecular target currently undisclosed by the sponsor.

Beyond the preview

Go deeper on SGB-OB03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGB-OB03.

Explore the full profile